ABSTRACT
In the last 2 decades, clinical genetics on hereditary colorectal syndromes has shifted from just a molecular characterization of the different syndromes to the estimation of the individual risk of cancer and appropriate risk reduction strategies. In the last years, new specific therapies for some subgroups of patients have emerged as very effective alternatives. At the same time, germline multigene panel testing by next-generation sequencing (NGS) technology has become the new gold standard for molecular genetics.
Subject(s)
Clinical Trials as Topic/standards , Colorectal Neoplasms/prevention & control , Genetic Predisposition to Disease , Mutation , Neoplasm Proteins/genetics , Practice Guidelines as Topic/standards , Colorectal Neoplasms/genetics , Humans , Medical Oncology , Societies, MedicalABSTRACT
De todas las neoplasias malignas de páncreas una de las menos frecuentes es el linfoma, el 70 por ciento de los casos son de tipo difuso de células grandes B. Establecer un correcto y rápido diagnóstico diferencial puede conducir a evitar técnicas quirúrgicas agresivas y al uso de una terapia adecuada habitualmente multidisciplinar incluyendo quimioterapia, cirugía y radioterapia que conduzcan a un pronóstico más favorable que el de otros tumores más habituales como el adenocarcinoma (AU)
